Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

Ferdinando Squitieri; Sara Orobello; Milena Cannella; Tiziana Martino; Pantaleo Romanelli; Giampiero Giovacchini; Luigi Frati; Luigi Mansi; Andrea Ciarmiello

doi:10.1007/s00259-009-1103-3

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

Ferdinando Squitieri, Sara Orobello, Milena Cannella, Tiziana Martino, Pantaleo Romanelli, Giampiero Giovacchini, Luigi Frati, Luigi Mansi, Andrea Ciarmiello

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration. Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated and 12 placebo-treated patients by MRI and ¹⁸F-f uoro-2-deoxy-d-glucose (FDG) PET scanning, according to fully automated protocols. We also investigated the influence of riluzole on peripheral growth factor blood levels. Results: Placebo-treated patients showed significantly greater proportional volume loss of grey matter and decrease in metabolic FDG uptake than patients treated with riluzole in all cortical areas (p

Original language	English
Pages (from-to)	1113-1120
Number of pages	8
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	36
Issue number	7
DOIs	https://doi.org/10.1007/s00259-009-1103-3
Publication status	Published - Jul 2009

Keywords

Brain-derived neurotrophic factor
FDG-PET scan
Neurotrophins
Transforming growth factor
Volumetric MRI

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-009-1103-3

Fingerprint Dive into the research topics of 'Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins'. Together they form a unique fingerprint.

Cite this

Squitieri, F., Orobello, S., Cannella, M., Martino, T., Romanelli, P., Giovacchini, G., Frati, L., Mansi, L., & Ciarmiello, A. (2009). Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. European Journal of Nuclear Medicine and Molecular Imaging, 36(7), 1113-1120. https://doi.org/10.1007/s00259-009-1103-3

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. / Squitieri, Ferdinando; Orobello, Sara; Cannella, Milena; Martino, Tiziana; Romanelli, Pantaleo; Giovacchini, Giampiero; Frati, Luigi; Mansi, Luigi; Ciarmiello, Andrea.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 7, 07.2009, p. 1113-1120.

Research output: Contribution to journal › Article › peer-review

Squitieri, F, Orobello, S, Cannella, M, Martino, T, Romanelli, P, Giovacchini, G, Frati, L, Mansi, L & Ciarmiello, A 2009, 'Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins', European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 7, pp. 1113-1120. https://doi.org/10.1007/s00259-009-1103-3

Squitieri, Ferdinando ; Orobello, Sara ; Cannella, Milena ; Martino, Tiziana ; Romanelli, Pantaleo ; Giovacchini, Giampiero ; Frati, Luigi ; Mansi, Luigi ; Ciarmiello, Andrea. / Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. In: European Journal of Nuclear Medicine and Molecular Imaging. 2009 ; Vol. 36, No. 7. pp. 1113-1120.

@article{98f89878852c4e2e8637d22aa53a30a7,

title = "Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins",

abstract = "Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration. Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated and 12 placebo-treated patients by MRI and 18F-f uoro-2-deoxy-d-glucose (FDG) PET scanning, according to fully automated protocols. We also investigated the influence of riluzole on peripheral growth factor blood levels. Results: Placebo-treated patients showed significantly greater proportional volume loss of grey matter and decrease in metabolic FDG uptake than patients treated with riluzole in all cortical areas (p",

keywords = "Brain-derived neurotrophic factor, FDG-PET scan, Neurotrophins, Transforming growth factor, Volumetric MRI",

author = "Ferdinando Squitieri and Sara Orobello and Milena Cannella and Tiziana Martino and Pantaleo Romanelli and Giampiero Giovacchini and Luigi Frati and Luigi Mansi and Andrea Ciarmiello",

year = "2009",

month = jul,

doi = "10.1007/s00259-009-1103-3",

language = "English",

volume = "36",

pages = "1113--1120",

journal = "European Journal of Pediatrics",

issn = "0340-6199",

publisher = "Springer Berlin Heidelberg",

number = "7",

}

TY - JOUR

T1 - Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

AU - Squitieri, Ferdinando

AU - Orobello, Sara

AU - Cannella, Milena

AU - Martino, Tiziana

AU - Romanelli, Pantaleo

AU - Giovacchini, Giampiero

AU - Frati, Luigi

AU - Mansi, Luigi

AU - Ciarmiello, Andrea

PY - 2009/7

Y1 - 2009/7

N2 - Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration. Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated and 12 placebo-treated patients by MRI and 18F-f uoro-2-deoxy-d-glucose (FDG) PET scanning, according to fully automated protocols. We also investigated the influence of riluzole on peripheral growth factor blood levels. Results: Placebo-treated patients showed significantly greater proportional volume loss of grey matter and decrease in metabolic FDG uptake than patients treated with riluzole in all cortical areas (p

AB - Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration. Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated and 12 placebo-treated patients by MRI and 18F-f uoro-2-deoxy-d-glucose (FDG) PET scanning, according to fully automated protocols. We also investigated the influence of riluzole on peripheral growth factor blood levels. Results: Placebo-treated patients showed significantly greater proportional volume loss of grey matter and decrease in metabolic FDG uptake than patients treated with riluzole in all cortical areas (p

KW - Brain-derived neurotrophic factor

KW - FDG-PET scan

KW - Neurotrophins

KW - Transforming growth factor

KW - Volumetric MRI

UR - http://www.scopus.com/inward/record.url?scp=67349146480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349146480&partnerID=8YFLogxK

U2 - 10.1007/s00259-009-1103-3

DO - 10.1007/s00259-009-1103-3

M3 - Article

C2 - 19280185

AN - SCOPUS:67349146480

VL - 36

SP - 1113

EP - 1120

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 7

ER -